Edward J. Dulac III
Equibles does not estimate personal net worth.
Get an email with a short summary when Intellia Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get NTLA alertsAbout Edward J. Dulac III
Edward J. Dulac III is recorded as CFO at Intellia Therapeutics, Inc. (NTLA). The proxy statement of Intellia Therapeutics, Inc. reports total compensation of $2,168,505 for Edward J. Dulac III in fiscal 2025, including a base salary of $526,000. Disclosed compensation is on record for 2 fiscal years. Intellia Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Intellia Therapeutics, Inc. includes Andrew D. Schiermeier (COO), James Basta (General Counsel), Michael P. Dube (Chief Accounting Officer) and 7 others.
Affiliation history
-
Current
Company network
Leadership on record at Intellia Therapeutics, Inc.
- Andrew D. Schiermeier COO
- James Basta General Counsel
- Michael P. Dube Chief Accounting Officer
- Bill Chase Board Member
- Brian Goff Board Member
- Georgia Keresty Board Member
- Georgia Keresty, Ph.D., M.P.H. Board Member
- John M. Leonard Board Member
- John M. Leonard, M.D. Board Member
- Muna Bhanji Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Intellia Therapeutics, Inc. (NTLA) | Executive Vice President, Chief Financial Officer and Treasurer | $526,000 | $2,168,505 |
| 2024 | Intellia Therapeutics, Inc. (NTLA) | Executive Vice President, Chief Financial Officer and Treasurer | $228,192 | $6,694,737 |
Recent activity
No call appearances or filed executive changes recorded yet.